Thursday, February 7, 2013
This week in
B cell lymphoma 2
Mouse and cell culture
studies suggest BCL-2 inhibitors could be useful for selectively killing
leukemia stem cells. In mice engrafted with human chronic myelogenous
leukemia (CML) stem cells, the pan-BCL-2 inhibitor sabutoclax
decreased stem cell burden and increased stem cell sensitivity to the
tyrosine kinase inhibitor Sprycel dasatinib compared with
vehicle. In CML stem cell-enriched primary acute myelogenous leukemia (AML)
samples, compared with non-stem cell-enriched AML samples, two related BCL-2
inhibitors, ABT-263 and ABT-737,
caused selective increases in cell death. Next steps could include a clinical
trial of BCL-2 inhibitors in combination with other antileukemia therapies.
Squibb Co. markets Sprycel to treat acute lymphoblastic
leukemia (ALL) and CML.
Laboratories and Roche's
Inc. unit have ABT-263 in Phase I/II testing or earlier to
treat various cancers. ABT-737 is a research reagent from Abbott.
Inc.'s sabutoclax is in preclinical development to treat
At least seven other companies have BCL-2 inhibitors in Phase II testing to
treat various cancers including leukemia and lymphoma.
Published online Feb. 7, 2013
Patent and licensing status
Goff, D.J. et al. Cell
Stem Cell; published online Jan. 17, 2013;
Contact: Catriona H.M. Jamieson, University of California,
San Diego, La Jolla, Calif.
Lagadinou, E.D. et al. Cell Stem Cell; published online Jan. 17, 2013;
Contact: Craig T. Jordan, University of Rochester Medical
Center, Rochester, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]